BackNeuroSense Therapeutics Ltd - Warrants (09/11/2026) Overview
NeuroSense Therapeutics Ltd - Warrants (09/11/2026)

NeuroSense Therapeutics Ltd - Warrants (09/11/2026) Return on Equity

Latest ROE for NeuroSense Therapeutics Ltd - Warrants (09/11/2026): 713.14% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

713.14%

Return on Equity

713.14%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

NeuroSense Therapeutics Ltd - Warrants (09/11/2026) (NRSNW) FAQ

As of the most recent data, NRSNW shows a ROE of 713.14%. That is above the sector sector average of -5.84%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about -5.84%. NeuroSense Therapeutics Ltd - Warrants (09/11/2026) is at 713.14%, which is higher that average. That is roughly 12301.1% above the sector mean. Use the comparison chart on this page to see how NRSNW stacks up against individual peers as well.

Check the historical chart to see whether NRSNW's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare NeuroSense Therapeutics Ltd - Warrants (09/11/2026) with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has NeuroSense Therapeutics Ltd - Warrants (09/11/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 713.14%) with ownership activity and broader fundamentals.